{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:32:19Z","timestamp":1794004339155,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81991492"],"award-info":[{"award-number":["81991492"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project Supported by Shanghai Municipal Science and Technology Major Project. An Innovation Grant from Fudan-Advaccine Join-Laboratory."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In situ vaccination (ISV) triggers antitumor immune responses using the patient\u2019s own cancer antigens, yet limited neoantigen release hampers its efficacy. Our novel combination therapy involves low-dose local cisplatin followed by ISV with a TLR7\/8\/9 agonist formulation (CR108), in which CR108 boosts and sustains the antitumor responses induced by the cisplatin-released neoantigens. In mouse models, the cisplatin+CR108 combination significantly outperformed cisplatin or CR108 alone in abrogating established 4T1 and B16 tumors. The synergistic antitumor effects of cisplatin and CR108 were accompanied by markedly increased tumor tertiary lymphatic structures (TLS) formation, higher levels of type I and III interferons and TNF-\u03b1 in serum, augmented T and B lymphocyte infiltration, antigen-presenting cell activation, as well as reduced functionally of exhausted T cells. Single-cell sequencing analysis uncovered a potential pathway for TLS to serve as a reservoir for functional antitumor effector T cells. Furthermore, cisplatin+CR108 combo therapy, but neither cisplatin nor CR108 alone, effectively inhibited the growth of treated 4T-1 tumor in an effector T cell-dependent manner. Notably, the combo therapy also suppressed the growth of distant untreated 4T-1 tumors, demonstrating systemic antitumor effects. Moreover, combo-therapy led to full regression of 4T-1 tumors in a large percentage of mice, who became strongly resistant to secondary tumor challenge, a clear indication of antitumor immunological memory. The cisplatin+CR108 combo therapy holds promise in converting \u201ccold\u201d tumors into \u201chot\u201d ones and eliciting robust antitumor immune responses in vivo.<\/jats:p>","DOI":"10.1038\/s41541-024-01055-z","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T23:45:55Z","timestamp":1737243955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["TLR7\/8\/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity"],"prefix":"10.1038","volume":"10","author":[{"given":"Shuting","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-1818","authenticated-orcid":false,"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,19]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"crossref","unstructured":"Gote, V., Nookala, A. R., Bolla, P.K. & Pal, D. Drug resistance in metastatic breast cancer: tumor targeted nanomedicine to the rescue. Int. J. Mol. Sci. 22, 4673 (2021).","DOI":"10.3390\/ijms22094673"},{"key":"1055_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj3671","volume":"8","author":"P Bonaventura","year":"2022","unstructured":"Bonaventura, P. et al. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci. Adv. 8, eabj3671 (2022).","journal-title":"Sci. Adv."},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim, M. K. et al. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186, 1127\u20131143 e1118 (2023).","journal-title":"Cell"},{"key":"1055_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.cell.2017.08.031","volume":"170","author":"J Haanen","year":"2017","unstructured":"Haanen, J. Converting cold into hot tumors by combining immunotherapies. Cell 170, 1055\u20131056 (2017).","journal-title":"Cell"},{"key":"1055_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"1055_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"1055_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert, L. et al. Challenges in neoantigen-directed therapeutics. Cancer Cell 41, 15\u201340 (2023).","journal-title":"Cancer Cell"},{"key":"1055_CR8","doi-asserted-by":"crossref","unstructured":"Chen, J. et al. In situ cancer vaccination using lipidoid nanoparticles. Sci. Adv. 7, eabf1244 (2021).","DOI":"10.1126\/sciadv.abf1244"},{"key":"1055_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2022.2019706","volume":"31","author":"C Karime","year":"2022","unstructured":"Karime, C. et al. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opin. Investig. Drugs 31, 1\u201313 (2022).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1055_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/med.21553","volume":"39","author":"MA Anwar","year":"2019","unstructured":"Anwar, M. A., Shah, M., Kim, J. & Choi, S. Recent clinical trends in Toll-like receptor targeting therapeutics. Med Res Rev. 39, 1053\u20131090 (2019).","journal-title":"Med Res Rev."},{"key":"1055_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).","journal-title":"Cell Death Dis."},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2020.04.020","volume":"108","author":"RC Walshaw","year":"2020","unstructured":"Walshaw, R. C., Honeychurch, J., Choudhury, A. & Illidge, T. M. Toll-like receptor agonists and radiation therapy combinations: an untapped opportunity to induce anticancer immunity and improve tumor control. Int J. Radiat. Oncol. Biol. Phys. 108, 27\u201337 (2020).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"1055_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22311-z","volume":"12","author":"B Bahmani","year":"2021","unstructured":"Bahmani, B. et al. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nat. Commun. 12, 1999 (2021).","journal-title":"Nat. Commun."},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","volume":"38","author":"S Grabosch","year":"2019","unstructured":"Grabosch, S. et al. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene 38, 2380\u20132393 (2019).","journal-title":"Oncogene"},{"key":"1055_CR15","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","volume":"20","author":"AR de Biasi","year":"2014","unstructured":"de Biasi, A. R., Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384\u20135391 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1055_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"1055_CR17","doi-asserted-by":"publisher","first-page":"689270","DOI":"10.3389\/fimmu.2021.689270","volume":"12","author":"W Kang","year":"2021","unstructured":"Kang, W. et al. Tertiary lymphoid structures in cancer: the double-edged sword role in antitumor immunity and potential therapeutic induction strategies. Front. Immunol. 12, 689270 (2021).","journal-title":"Front. Immunol."},{"key":"1055_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"1055_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"1055_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675538","volume":"12","author":"S Aoyama","year":"2021","unstructured":"Aoyama, S., Nakagawa, R., Mule, J. J. & Mailloux, A. W. Inducible tertiary lymphoid structures: promise and challenges for translating a new class of immunotherapy. Front. Immunol. 12, 675538 (2021).","journal-title":"Front. Immunol."},{"key":"1055_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441\u2013457 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1055_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.immuni.2021.12.007","volume":"55","author":"RA Chaurio","year":"2022","unstructured":"Chaurio, R. A. et al. TGF-beta-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity 55, 115\u2013128 e119 (2022).","journal-title":"Immunity"},{"key":"1055_CR23","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.celrep.2021.109422","volume":"36","author":"AB Rodriguez","year":"2021","unstructured":"Rodriguez, A. B. et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36, 109422 (2021).","journal-title":"Cell Rep."},{"key":"1055_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8114","volume":"6","author":"JD Peske","year":"2015","unstructured":"Peske, J. D. et al. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114 (2015).","journal-title":"Nat. Commun."},{"key":"1055_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1055_CR26","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","volume":"21","author":"NA Giraldo","year":"2015","unstructured":"Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031\u20133040 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1055_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1055_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911\u2013926 (2022).","journal-title":"Nat. Cancer"},{"key":"1055_CR29","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman, W. H. et al. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity 56, 2254\u20132269 (2023).","journal-title":"Immunity"},{"key":"1055_CR30","doi-asserted-by":"crossref","unstructured":"Cai, D. et al. Turning tertiary lymphoid structures (TLS) into hot spots: values of TLS in gastrointestinal tumors. Cancers 15, 367 (2023).","DOI":"10.3390\/cancers15020367"},{"key":"1055_CR31","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00204-015-1633-3","volume":"89","author":"S Zhu","year":"2015","unstructured":"Zhu, S., Pabla, N., Tang, C., He, L. & Dong, Z. DNA damage response in cisplatin-induced nephrotoxicity. Arch. Toxicol. 89, 2197\u20132205 (2015).","journal-title":"Arch. Toxicol."},{"key":"1055_CR32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.amjsurg.2011.06.027","volume":"202","author":"SM Cohen","year":"2011","unstructured":"Cohen, S. M. et al. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am. J. Surg. 202, 646\u2013652 (2011).","journal-title":"Am. J. Surg."},{"key":"1055_CR33","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. J. Immunother. Cancer 10, e003939 (2022).","DOI":"10.1136\/jitc-2021-003939"},{"key":"1055_CR34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4161\/onci.20931","volume":"1","author":"E Vacchelli","year":"2012","unstructured":"Vacchelli, E. et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1, 894\u2013907 (2012).","journal-title":"Oncoimmunology"},{"key":"1055_CR35","doi-asserted-by":"crossref","unstructured":"Sagiv-Barfi, I. et al. Eradication of spontaneous malignancy by local immunotherapy. Sci. Transl. Med. 10, eaan4488 (2018).","DOI":"10.1126\/scitranslmed.aan4488"},{"key":"1055_CR36","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.21037\/atm-21-491","volume":"9","author":"M Zawit","year":"2021","unstructured":"Zawit, M. et al. Current status of intralesional agents in treatment of malignant melanoma. Ann. Transl. Med. 9, 1038 (2021).","journal-title":"Ann. Transl. Med."},{"key":"1055_CR37","doi-asserted-by":"publisher","first-page":"e2300688","DOI":"10.1002\/adhm.202300688","volume":"12","author":"Y He","year":"2023","unstructured":"He, Y. et al. STING protein-based in situ vaccine synergizes CD4(+) T, CD8(+) T, and NK cells for tumor eradication. Adv. Health. Mater. 12, e2300688 (2023).","journal-title":"Adv. Health. Mater."},{"key":"1055_CR38","doi-asserted-by":"publisher","first-page":"120542","DOI":"10.1016\/j.biomaterials.2020.120542","volume":"268","author":"J Zhao","year":"2021","unstructured":"Zhao, J. et al. In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy. Biomaterials 268, 120542 (2021).","journal-title":"Biomaterials"},{"key":"1055_CR39","doi-asserted-by":"crossref","unstructured":"Gu-Trantien, C. et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight 2, e91487 (2017).","DOI":"10.1172\/jci.insight.91487"},{"key":"1055_CR40","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1172\/JCI67428","volume":"123","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien, C. et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873\u20132892 (2013).","journal-title":"J. Clin. Invest."},{"key":"1055_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19973-6","volume":"11","author":"M Zhang","year":"2020","unstructured":"Zhang, M. et al. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nat. Commun. 11, 6119 (2020).","journal-title":"Nat. Commun."},{"key":"1055_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","volume":"184","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 184, 404\u2013421.e416 (2021).","journal-title":"Cell"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01055-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01055-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01055-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T11:40:15Z","timestamp":1737286815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01055-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01055-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,19]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Some of the contents in the manuscript have been used for a patent application. S.W., G.Z., Z.K., and B.W. are listed as inventors. Advaccine Biopharmaceutics (Suzhou) Co., LTD and Fudan University are joint applicants for the patent application PCT\/CN2023\/113027. The patent application is currently at the publication stage. This potential conflict of interest has been disclosed to the NPJ Vaccines editorial board. R.X., Y.W.Z., S.S.Z., Z.Y.Z., S.J.Z., Y.Z., C.Z., Y.X., S.R., and X.G. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}